SCIENTIFIC REPORTS

OPEN

Author Correction: Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer

Asmus Heumann^{1,2}, Özge Kaya¹, Christoph Burdelski², Claudia Hube-Magg¹, Martina Kluth¹, Dagmar S. Lang¹, Ronald Simon¹, Burkhard Beyer³, Imke Thederan³, Guido Sauter¹, Jakob R. Izbic², Andreas M. Luebke¹, Andrea Hinsch¹, Frank Jacobsen¹, Corinna Wittmer¹, Franziska Büscheck¹, Doris Höflmayer¹, Sarah Minner¹, Maria Christina Tsourlakis¹, Thorsten Schlomm^{3,4} & Waldemar Wilczak¹

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-017-02279-x>, published online 17 May 2017

The Article contains errors.

Reference 12 is cited to support a statement that YB-1 is up-regulated in different cancers, and that YB-1 overexpression is linked to adverse clinical outcomes. However, this reference reports that the results are dependent on the antibody against YB-1. As such the authors do not think its citation in the original text is appropriate and wish to remove it.

As a result, in the Introduction,

“Given the “oncogenic” nature of these functions, it is not unexpected that up-regulation of YB-1 has been reported in virtually all human cancer types, including epithelial and mesenchymal solid cancers^{7,8,9,10,11,12,13,14,15,16} as well as haematological diseases like lymphoma and leukaemia^{17,18}. YB-1 overexpression has been linked to adverse clinical outcome and poor therapy response in most of them^{7,8,9,10,11,12,14,15,17,18}, making it a promising prognostic biomarker in cancer.”

should read:

“Given the “oncogenic” nature of these functions, it is not unexpected that up-regulation of YB-1 has been reported in virtually all human cancer types, including epithelial and mesenchymal solid cancers^{7,8,9,10,11,13,14,15,16} as well as haematological diseases like lymphoma and leukaemia^{17,18}. YB-1 overexpression has been linked to adverse clinical outcome and poor therapy response in most of them^{7,8,9,10,11,14,15,17,18}, making it a promising prognostic biomarker in cancer.”

Additionally, the following sentence citing this reference should be included in the Materials and Methods section, under the subheading ‘Immunocytochemistry’:

¹Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. ²General, Visceral and Thoracic Surgery Department and Clinic, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. ³Martini-Clinic, Prostate Cancer Centre, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. ⁴Department of Urology, Section for translational Prostate Cancer Research, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. Asmus Heumann and Özge Kaya contributed equally. Correspondence and requests for materials should be addressed to R.S. (email: R.Simon@uke.de)

Published online: 21 August 2018

“Of note, this antibody has been shown to detect an epitope also present on heterogeneous nuclear ribonucleoprotein A1 (Wooley *et al.*¹²).”

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018